Selinexor (Nexpovio®) Infosheet

This Horizons Infosheet contains information about selinexor, a drug being investigated for the treatment of myeloma.

Update April 2024: since this Infosheet was updated, the National Institute for Health and Care Excellence (NICE) has approved selinexor for use in myeloma, in combination with other treatments. The combinations are approved for use at second, third and fifth line in eligible patients. Read more here: Patient advocacy news.

This Infosheet covers key questions about selinexor, including: 

  • What is selinexor? 
  • How does selinexor work? 
  • How is selinexor given? 
  • What evidence exists to support the use of selinexor? 
  • What are the possible known side effects of selinexor? 
  • Is selinexor currently available in any UK clinical trials? 
  • Availability of selinexor in the UK 
  • Future directions 

Key points you can read about in this Infosheet include:  

  • Selinexor is a drug being investigated for the treatment of myeloma 
  • Selinexor is the first in a new class of drugs called SINE compounds. It works by blocking the movement of particular proteins within cells. The aim is to use this to stop myeloma cells from multiplying out of control 
  • Clinical trials with selinexor have so far been promising, indicating selinexor in combination with other drugs is a potential treatment option in patients with relapsed and refractory myeloma. Trials are continuing to provide further information about selinexor’s effectiveness and side effects, and to compare it with existing myeloma treatments 
  • Selinexor can cause serious side effects, which have so far included effects on blood cell counts, digestive effects, and fatigue 

Myeloma UK Selinexor Horizons Infosheet

PDF / 234KB Download
Close-up photograph of a hand holding a mobile phone.

Stay in touch

We’d love to stay in touch. Join our mailing list to receive updates from Myeloma UK including our monthly newsletter and updates about our services, research, campaigns and other ways you can get involved.